Skip to main content
Clinical Trials/CTRI/2008/091/000046
CTRI/2008/091/000046
Completed
Phase 2

Intravenous autologous bone marrow derived stem cells therapy for patients with acute ischemic stroke: A multi-institutional project.

Department of Biotechnology Ministry of Science and Technology Government of India New Delhi0 sites120 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Department of Biotechnology Ministry of Science and Technology Government of India New Delhi
Enrollment
120
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Department of Biotechnology Ministry of Science and Technology Government of India New Delhi

Eligibility Criteria

Inclusion Criteria

  • 1\. Sudden onset of focal neurologic deficit or impairment of consciousness,
  • 2\. Computerized tomographic or MRI scan of the head showing no haematoma, and relevant lesions within the MCA and ACA territory.
  • 3\. Age between 18 and 70 years
  • 4\. Seven days or more but less than 30 days has passed since the onset of the qualifying event,
  • 5\. Glasgow Coma Scale score of above 8 at the time of randomization (Appendix 15\), in aphasic Eye and Motor score of more than 6,
  • 6\. Modified Barthel index score of 50 or less at the time of randomization (Appendix 8\).
  • 7\. NIHSS score of 7 or more points and inability to walk unaided or raise upper limb by 900 (Appendix 17\)
  • 8\. Patient is stable: A patient will be defined as stable when he has normal respiration, is afebrile, has BP less than mean arterial pressure of 125mm Hg (but no hypotension defined as systolic BP \<90mmHg), has fasting venous blood sugar level less than 200mg% and normal urea/electrolytes for at least 48 hours.

Exclusion Criteria

  • 1\. Lacunar syndrome
  • 2\. Intubation
  • 3\. Posterior Circulation Stroke
  • 4\. Co\-morbidity likely to limit survival to less than three years e.g. malignant diseases, hepatic or renal failure
  • 5\. Pre\-stroke disability leading to dependence on others for activities of daily living,
  • 6\. Inaccessibility for follow\-up
  • 7\. Allergy to local anaesthetic
  • 8\. Unwillingness to provide written informed consent by self or assent by next of kin.
  • 9\. Symptom of Acute myocardial infarction or acute involvement of any other organ.
  • 10\. Pregnancy

Outcomes

Primary Outcomes

Not specified

Similar Trials